• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy of tocilizumab treatment in severely ill COVID-19 patients.

作者信息

Zhao Jie, Cui Wei, Tian Bao-Ping

机构信息

Department of Critical Care Medicine, The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Rd., Hangzhou, 310009, Zhejiang, China.

出版信息

Crit Care. 2020 Aug 27;24(1):524. doi: 10.1186/s13054-020-03224-7.

DOI:10.1186/s13054-020-03224-7
PMID:32854738
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7450680/
Abstract
摘要

相似文献

1
Efficacy of tocilizumab treatment in severely ill COVID-19 patients.托珠单抗治疗重症 COVID-19 患者的疗效。
Crit Care. 2020 Aug 27;24(1):524. doi: 10.1186/s13054-020-03224-7.
2
The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.COVID-19 病毒感染管理的 COVIRL002 试验-托珠单抗：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Sep 3;21(1):758. doi: 10.1186/s13063-020-04680-w.
3
A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.一项旨在评估托珠单抗治疗重症 COVID-19 肺炎患者的疗效和安全性的前瞻性、随机、双盲、安慰剂对照试验（TOC-COVID）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):470. doi: 10.1186/s13063-020-04447-3.
4
Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.抗白细胞介素药物治疗重症 COVID-19 患者（COV-AID）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):468. doi: 10.1186/s13063-020-04453-5.
5
[COVID-19: Still a place for tocilizumab?].[新型冠状病毒肺炎：托珠单抗仍有一席之地？]
Rev Med Interne. 2021 Feb;42(2):73-78. doi: 10.1016/j.revmed.2020.11.016. Epub 2020 Nov 27.
6
Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial.COVID-19 住院患者使用托珠单抗的疗效：CORIMUNO-TOCI-1 随机临床试验的随访。
JAMA Intern Med. 2021 Sep 1;181(9):1241-1243. doi: 10.1001/jamainternmed.2021.2209.
7
Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis.托珠单抗治疗重症和危重症 COVID-19 的疗效和安全性：系统评价和荟萃分析。
Expert Rev Clin Immunol. 2021 May;17(5):499-511. doi: 10.1080/1744666X.2021.1908128. Epub 2021 Apr 7.
8
Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment.托珠单抗治疗期间伴 MOG 抗体相关疾病的良性 SARS-CoV-2 感染。
Mult Scler Relat Disord. 2020 Nov;46:102592. doi: 10.1016/j.msard.2020.102592. Epub 2020 Oct 21.
9
Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.羟氯喹和托珠单抗治疗 COVID-19 患者：一项观察性研究。
PLoS One. 2020 Aug 13;15(8):e0237693. doi: 10.1371/journal.pone.0237693. eCollection 2020.
10
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis.托珠单抗治疗 COVID-19 患者的疗效和安全性：一项实时系统评价和荟萃分析。
Clin Microbiol Infect. 2021 Feb;27(2):215-227. doi: 10.1016/j.cmi.2020.10.036. Epub 2020 Nov 5.

引用本文的文献

1
The association between tocilizumab therapy and the development of thrombosis in critically ill patients with COVID-19: a multicenter, cohort study.托珠单抗治疗与 COVID-19 重症患者血栓形成的关联：一项多中心队列研究。
Sci Rep. 2024 Feb 6;14(1):3037. doi: 10.1038/s41598-024-53087-z.
2
Quantum DFT studies on the drug delivery of favipiravir using pristine and functionalized chitosan nanoparticles.使用未功能化和功能化壳聚糖纳米粒子进行法匹拉韦药物输送的量子 DFT 研究。
Sci Rep. 2023 Dec 11;13(1):21984. doi: 10.1038/s41598-023-49298-5.
3
The use of Tocilizumab in COVID-19 critically ill patients with renal impairment: a multicenter, cohort study.

本文引用的文献

1
Single-Cell Sequencing of Peripheral Mononuclear Cells Reveals Distinct Immune Response Landscapes of COVID-19 and Influenza Patients.外周血单核细胞单细胞测序揭示 COVID-19 和流感患者不同的免疫反应图谱。
Immunity. 2020 Sep 15;53(3):685-696.e3. doi: 10.1016/j.immuni.2020.07.009. Epub 2020 Jul 19.
2
Population health, economics and ethics in the age of COVID-19.COVID-19 时代的人口健康、经济学和伦理学
BMJ Glob Health. 2020 Jul;5(7). doi: 10.1136/bmjgh-2020-003259.
3
A race to determine what drives COVID-19 severity.一场确定是什么因素导致新冠病毒疾病严重程度的竞赛。
托珠单抗在 COVID-19 合并肾功能损害重症患者中的应用：一项多中心队列研究。
Ren Fail. 2023;45(2):2268213. doi: 10.1080/0886022X.2023.2268213. Epub 2023 Oct 23.
4
Health system factors related to COVID-19 mortality in Eastern India: Hospital-based cross-sectional study.印度东部与新冠病毒疾病死亡率相关的卫生系统因素：基于医院的横断面研究。
J Family Med Prim Care. 2023 Jul;12(7):1331-1335. doi: 10.4103/jfmpc.jfmpc_1956_22. Epub 2023 Jul 14.
5
Clinical Consequences for Individuals Treated with Tocilizumab for Serious COVID-19 Infection.托珠单抗治疗重症 COVID-19 感染患者的临床后果。
Healthcare (Basel). 2023 Feb 17;11(4):607. doi: 10.3390/healthcare11040607.
6
Advanced Molecular Tweezers with Lipid Anchors against SARS-CoV-2 and Other Respiratory Viruses.具有脂质锚定结构的新型分子镊子对严重急性呼吸综合征冠状病毒2及其他呼吸道病毒的作用
JACS Au. 2022 Sep 6;2(9):2187-2202. doi: 10.1021/jacsau.2c00220. eCollection 2022 Sep 26.
7
Beneficial of adding Tocilizumab to standard care in critical forms of Covid-19 pneumonia: Study on paired series.托珠单抗联合标准治疗对新冠肺炎重症肺炎的疗效：配对系列研究。
Tunis Med. 2022;100(4):309-312.
8
Efficacy of tocilizumab in the treatment of COVID-19: An umbrella review.托珠单抗治疗 COVID-19 的疗效：一项伞状评价。
Rev Med Virol. 2022 Nov;32(6):e2388. doi: 10.1002/rmv.2388. Epub 2022 Aug 27.
9
Efficacy of Single Tocilizumab Administration in an 88-Year-Old Patient with Severe COVID-19 and a Mini Literature Review.托珠单抗单药治疗一名88岁重症新型冠状病毒肺炎患者的疗效及文献综述
Geriatrics (Basel). 2022 Feb 21;7(1):22. doi: 10.3390/geriatrics7010022.
10
Therapeutic role of immunomodulators during the COVID-19 pandemic- a narrative review.免疫调节剂在 COVID-19 大流行期间的治疗作用——叙述性综述。
Postgrad Med. 2022 Mar;134(2):160-179. doi: 10.1080/00325481.2022.2033563. Epub 2022 Feb 12.
Nature. 2020 Jul;583(7816):366-368. doi: 10.1038/d41586-020-01915-3.
4
Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.新型冠状病毒病 2019（COVID-19）的病理生理学、传播、诊断和治疗：综述。
JAMA. 2020 Aug 25;324(8):782-793. doi: 10.1001/jama.2020.12839.
5
Immune status could determine efficacy of COVID-19 therapies.免疫状态可能决定新冠病毒治疗的疗效。
Nat Rev Drug Discov. 2020 Jul;19(7):431-434. doi: 10.1038/d41573-020-00110-3.
6
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure.COVID-19 患者严重呼吸衰竭的复杂免疫失调。
Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3. doi: 10.1016/j.chom.2020.04.009. Epub 2020 Apr 21.